KR20230079151A - Kdm1a 에 의해 매개되는 질환 치료용 약학 제형 - Google Patents

Kdm1a 에 의해 매개되는 질환 치료용 약학 제형 Download PDF

Info

Publication number
KR20230079151A
KR20230079151A KR1020237014383A KR20237014383A KR20230079151A KR 20230079151 A KR20230079151 A KR 20230079151A KR 1020237014383 A KR1020237014383 A KR 1020237014383A KR 20237014383 A KR20237014383 A KR 20237014383A KR 20230079151 A KR20230079151 A KR 20230079151A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
compound
amount
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014383A
Other languages
English (en)
Korean (ko)
Inventor
에이미 테퍼
카산드라 셀라트카
패트리샤 술리악
파라그 베드
남라타 보라
Original Assignee
이마고 바이오사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이마고 바이오사이언시즈 인코포레이티드 filed Critical 이마고 바이오사이언시즈 인코포레이티드
Publication of KR20230079151A publication Critical patent/KR20230079151A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237014383A 2020-10-01 2021-10-01 Kdm1a 에 의해 매개되는 질환 치료용 약학 제형 Pending KR20230079151A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086353P 2020-10-01 2020-10-01
US63/086,353 2020-10-01
PCT/US2021/053141 WO2022072811A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a

Publications (1)

Publication Number Publication Date
KR20230079151A true KR20230079151A (ko) 2023-06-05

Family

ID=80951023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014383A Pending KR20230079151A (ko) 2020-10-01 2021-10-01 Kdm1a 에 의해 매개되는 질환 치료용 약학 제형

Country Status (10)

Country Link
US (1) US20230293495A1 (cg-RX-API-DMAC10.html)
EP (1) EP4221704B1 (cg-RX-API-DMAC10.html)
JP (1) JP7848195B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230079151A (cg-RX-API-DMAC10.html)
CN (1) CN116367831A (cg-RX-API-DMAC10.html)
AU (1) AU2021351536A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023005987A2 (cg-RX-API-DMAC10.html)
CA (1) CA3193661A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023003783A (cg-RX-API-DMAC10.html)
WO (1) WO2022072811A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
CN104784180A (zh) 2008-07-28 2015-07-22 武田药品工业株式会社 药物组合物
JP4816828B2 (ja) * 2009-03-30 2011-11-16 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
CA2848493A1 (en) * 2011-09-14 2013-03-21 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
JP6727216B2 (ja) * 2015-02-12 2020-07-22 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのｋｄｍ１ａ阻害剤
US20190070172A1 (en) * 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
CA3021678A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
CN111194306B (zh) * 2016-08-16 2023-05-16 伊美格生物科学公司 用于制备kdm1a抑制剂的方法和过程
MX2022007113A (es) * 2019-12-09 2022-07-11 Imago Biosciences Inc Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.

Also Published As

Publication number Publication date
MX2023003783A (es) 2023-04-26
JP7848195B2 (ja) 2026-04-20
CA3193661A1 (en) 2022-04-07
WO2022072811A1 (en) 2022-04-07
AU2021351536A1 (en) 2023-05-04
JP2023544327A (ja) 2023-10-23
EP4221704B1 (en) 2025-09-24
EP4221704A4 (en) 2024-11-06
US20230293495A1 (en) 2023-09-21
BR112023005987A2 (pt) 2023-05-02
EP4221704A1 (en) 2023-08-09
CN116367831A (zh) 2023-06-30

Similar Documents

Publication Publication Date Title
RU2405540C1 (ru) Таблетка с высоким содержанием лекарственного препарата
EP1441713B2 (en) Modified release tamsulosin tablets
EP3409272B1 (en) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
US20230293495A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
JP7812785B2 (ja) Ｔｙｋ２阻害薬の剤形
AU2018326596A1 (en) High concentration dosage forms of pridopidine
CN102137663B (zh) 抑制变色的稳定的药物制剂
EP3749286A1 (en) A pharmaceutical composition comprising metamizole, drotaverine, and caffeine
EP2514422B1 (en) Elution stabilized teneligliptin preparation
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
KR20160060764A (ko) 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제
BR112020019425A2 (pt) Composição farmacêutica compreendendo meta-arsenito e método de fabricação
CN103717209A (zh) 速释的含普拉格雷的稳定的口服药物组合物
AU2014326142B2 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
KR20180036633A (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
KR20150059720A (ko) 아나글립틴 함유 제제
KR20160092956A (ko) 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제
CN101485637B (zh) 秋水仙碱骨架控释片或胶囊
CN105311635A (zh) 可调控释放度的高载药量的医药组合物及其制备方法
EA051661B1 (ru) Фармацевтическая композиция для лечения заболеваний, опосредованных kdm1a
EP4736851A1 (en) Levodopa-benserazide hydrochloride composition and preparation therefor
JP2025524357A (ja) 多数の顆粒
JP2025036080A (ja) グアンファシンを含む医薬組成物及びその製造方法
WO2025206292A1 (ja) アコチアミド又はその塩高含有錠剤
JP2022536955A (ja) ジクロフェナミド組成物及び使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230427

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240930

Comment text: Request for Examination of Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241002

Comment text: Request for Examination of Application